TABLE 2.
Association of PPS and clinicopathological characteristics in patients with GCLM after hepatectomy.
| Clinicopathological features | All cases (n = 108) |
Group 0 (n = 26) |
Group 1 (n = 48) |
Group 2 (n = 34) |
P-value |
| Age ≥ 65.0 < 65.0 |
63 (58.7) 45 (41.3) |
7 (26.9) 19 (73.1) |
28 (58.3) 20 (41.7) |
28 (82.3) 6 (17.7) |
P < 0.001 |
| Gender Male Female |
84 (77.6) 24 (22.4) |
19 (73.1) 7 (26.9) |
38 (79.1) 10 (20.9) |
27 (79.4) 7 (20.6) |
0.769 |
| BMI (kg/m2) < 18.5 ≥ 18.5 |
16 (14.8) 92 (85.2) |
2 (7.7) 24 (92.3) |
6 (12.5) 42 (87.5) |
8 (23.5) 26 (76.5) |
0.012 |
| Serum albumin (g/dL) ≥ 3.5 < 3.5 |
83 (76.8) 25 (23.2) |
42 (72.4) 5 (19.2) |
42 (72.4) 11 (22.9) |
44 (78.6) 9 (26.5) |
0.091 |
| CEA (ng/mL) ≥ 5.0 < 5.0 |
61 (56.5) 47 (43.5) |
15 (57.6) 11 (42.4) |
26 (54.2) 22 (45.8) |
20 (58.8) 14 (51.2) |
0.540 |
| Tumor location of GC Upper Middle/Lower |
34 (31.4) 74 (68.6) |
9 (34.6) 17 (65.4) |
14 (29.2) 34 (70.8) |
11 (32.3) 23 (67.7) |
0.601 |
| Lauren Classification Intestinal-type Diffused-type Mixed |
54 (50.0) 33 (30.5) 21 (19.5) |
12 (46.1) 9 (34.6) 5 (19.3) |
25 (52.0) 14 (29.2) 9 (18.8) |
17 (50.0) 10 (29.4) 7 (20.6) |
0.553 |
| Timing of liver metastases metachronous synchronous |
67 (62.0) 41 (38.0) |
17 (65.3) 9 (34.7) |
29 (60.4) 19 (39.6) |
21 (61.7) 13 (38.3) |
0.308 |
| Number of liver metastases ≤ 1 >1 |
72 (66.7) 36 (33.3) |
14 (53.8) 12 (46.2) |
31 (64.6) 17 (35.4) |
27 (79.4) 7 (20.6) |
0.002 |
| Maximum tumor size of the liver metastasis < 3 ≥ 3 |
68 (62.9) 40 (37.1) |
17 (65.3) 9 (34.7) |
28 (58.3) 20 (41.7) |
24 (70.6) 10 (29.4) |
0.304 |
| Type of hepatectomy Minor Major |
86 (79.6) 22 (20.4) |
20 (80.8) 6 (19.2) |
40 (83.3) 8 (16.7) |
25 (76.4) 9 (23.6) |
0.513 |
| Neoadjuvant chemotherapy No Yes |
48 (44.3) 60 (55.7) |
12 (42.3) 15 (57.7) |
20 (41.7) 28 (58.3) |
17 (50.0) 17 (50.0) |
0.446 |
| Adjuvant chemotherapy No Yes (Systemic chemotherapy/HAIC/Systemic chemotherapy + HAIC) |
35 (32.5) 73 (67.5) |
9 (30.8) 18 (69.2) |
18 (37.5) 30 (62.5) |
10 (29.5) 24 (70.5) |
0.217 |
PPS, Peking prognostic score; GCLM, gastric cancer liver metastasis; BMI, body mass index; GC, gastric cancer; HAIC, hepatic artery infusion chemotherapy.